Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 14/20 | 0.36 |
| ▸ | MTOR | P42345 | 13/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
| ▸ | SCD | O00767 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.33 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.33 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | JAK3 | P52333 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19706138 | 0.89 | WNT3A (0.33) | HCRTR1GPR119HRH3JAK3 | |
| SCHEMBL19670402 | 0.85 | PIK3CA (0.37) | PIK3CAMTORPIK3CDPIK3CGSCD | |
| SCHEMBL16754526 | 0.84 | PIK3CA (0.37) | PIK3CAMTORPIK3CDPIK3CGSCD | |
| SCHEMBL19706176 | 0.84 | PIK3CA (0.42) | PIK3CAMTORPIK3CDPIK3CGSCD | |
| SCHEMBL19670522 | 0.78 | PIK3CA (0.38) | PIK3CAMTORPIK3CDPIK3CG | |
| SCHEMBL19670633 | 0.77 | WNT3A (0.34) | PIK3CAMTORPIK3CDPIK3CGSCD | |
| SCHEMBL19670673 | 0.75 | JAK3 (0.33) | PIK3CAMTORKCNH2JAK3 | |
| SCHEMBL19670462 | 0.75 | MTOR (0.40) | PIK3CAMTORPIK3CDPIK3CGSCD | |
| SCHEMBL16754298 | 0.74 | WNT3A (0.38) | HCRTR1JAK3 | |
| SCHEMBL19670481 | 0.74 | KARS1 (0.41) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2020-03-17 | — | — | US | disclosed |
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2017-12-14 | — | — | US | disclosed |
| US-9834558-B2 | Substituted bridged urea analogs as sirtuin modulators | GLAXOSMITHKLINE LLC (US) | 2017-12-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170355697-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | PIK3CA 3691/4885MTOR 433/4885PIK3CD 3327/4885 |
| US-10590135-B2 | Substituted bridged urea analogs as sirtuin modulators | SIRT1, SIRT3, SIRT2 | PIK3CA 3691/4885MTOR 433/4885PIK3CD 3327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.